Comparative Pharmacology
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOCAINE.
LARYNGOTRACHEAL ANESTHESIA KIT vs LIDOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
Lidocaine is a sodium channel blocker that inhibits the influx of sodium ions into cardiac Purkinje fibers and myocytes, thereby stabilizing the neuronal membrane and decreasing automaticity. It also exhibits local anesthetic effects by reversibly binding to voltage-gated sodium channels in nerve cell membranes, blocking impulse conduction.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
For ventricular arrhythmias: IV bolus 1-1.5 mg/kg, then continuous infusion 1-4 mg/min. For local anesthesia: 0.5-2% solution, max 4.5 mg/kg (300 mg) without epinephrine, 7 mg/kg (500 mg) with epinephrine.
None Documented
None Documented
Clinical Note
moderateLidocaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lidocaine is combined with Fluticasone propionate."
Clinical Note
moderateLidocaine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Lidocaine."
Clinical Note
moderateLidocaine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Lidocaine."
Clinical Note
moderateLidocaine + Erythromycin
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Terminal elimination half-life 1.5-2 hours (normal hepatic function). In CHF or hepatic impairment, prolonged to 6-8 hours; in neonates, 3-6 hours. Context: rapid redistribution after IV bolus (alpha half-life ~8 min) accounts for brief clinical effect, while terminal half-life determines accumulation with infusion.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Renal excretion of metabolites: 4-hydroxyxylidine (70-80% renal, 10-20% biliary/fecal), unchanged lidocaine <10% renal. Total renal elimination ~90% (as metabolites), biliary/fecal ~10%.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)
"The metabolism of Erythromycin can be decreased when combined with Lidocaine."